8.60
price down icon0.69%   -0.06
after-market  After Hours:  8.60 
loading
Bausch Health Companies Inc stock is currently priced at $8.60, with a 24-hour trading volume of 2.15M. It has seen a -0.69% decreased in the last 24 hours and a -8.32% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $8.75 pivot point. If it approaches the $8.57 support level, significant changes may occur.

Bausch Health Companies Inc Stock (BHC) Financials Data

Bausch Health Companies Inc (BHC) Revenue 2024

BHC reported a revenue (TTM) of $8.76 billion for the quarter ending December 31, 2023, a +7.79% rise year-over-year.
loading

Bausch Health Companies Inc (BHC) Net Income 2024

BHC net income (TTM) was -$592.00 million for the quarter ending December 31, 2023, a -163.11% decrease year-over-year.
loading

Bausch Health Companies Inc (BHC) Cash Flow 2024

BHC recorded a free cash flow (TTM) of $760.00 million for the quarter ending December 31, 2023, a +176.31% increase year-over-year.
loading

Bausch Health Companies Inc (BHC) Earnings per Share 2024

BHC earnings per share (TTM) was -$1.62 for the quarter ending December 31, 2023, a -161.29% decline year-over-year.
loading
Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal. The company also develops and markets products that treat gastrointestinal and hepatologic conditions comprising hepatic encephalopathy, irritable bowel syndrome with diarrhea, traveler's diarrhea, opioid-induced constipation, ulcerative colitis, and others. In addition, it offers eye health products, such as contact lens; products that treat various eye conditions, including glaucoma, eye allergies, conjunctivitis, dry eye, and retinal diseases; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for the treatment of cataracts, and vitreous and retinal eye conditions. Further, the company provides products in the therapeutic areas of epilepsy, migraines, depression, chronic pain, and rare diseases such, as huntington's disease; and oral health products for adult periodontitis and mouth dryness, as well as teeth-whitening. Additionally, it offers eye drops; skin care products, including moisturizers; and eye vitamins and mineral supplements, as well as neurology products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. was founded in 1983 and is headquartered in Laval, Canada.
$13.57
price up icon 1.19%
$72.00
price down icon 6.12%
$55.80
price down icon 0.29%
drug_manufacturers_specialty_generic RDY
$70.91
price down icon 0.56%
$11.12
price up icon 0.18%
$132.54
price down icon 0.52%
Cap:     |  Volume (24h):